[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"circulating-tumor-dna\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:circulating-tumor-dna":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,74,100,123,143,166,190,213,243,268,293],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100549505","circulating-tumor-dna-based-adjuvant-chemotherapy-in-stage-ii-colon-cancer-patients-the-medocc-create-trial-100549505",false,"NCT06434896","Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial","CrEATE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Informed consent for PLCRC with specific consent for:\n\n  * additional blood withdrawals\n  * collection and use of tissue for scientific research\n  * invitation for future (experimental) research within the cohort, including TwiCs studies\n* Inclusion in observational PLCRC -MEDOCC substudy\n* Histological confirmed stage II colon cancer\n* Fit enough to receive treatment with combination chemotherapy (fluoropyrimidine and oxaliplatin) according to the treating physician\n\nExclusion Criteria:\n\n* Indication for adjuvant chemotherapy according to treating physician\n* Another malignancy in previous 5 years, with the exception of treated carcinoma in situ or skin cancer other than melanoma\n* Incomplete primary tumor resection (R1 or R2 resection)\n* Contra-indication for fluoropyrimidines or oxaliplatin\n* Pregnancy","ALL","18 Years",{"count":19,"type":20},1320,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the observational PLCRC-MEDOCC substudy. In this study, blood is collected before surgery, after surgery and during follow-up. Within PLCRC-MEDOCC, patients with stage II colon cancer that are not considered to have an indication for adjuvant chemotherapy, can be included in the MEDOCC-CrEATE subcohort under the condition that they gave informed consent in PLCRC for biobanking of tissue and for future studies (Trial within Cohorts design).\n\nPatients included in MEDOCC-CrEATE will be randomized 1:1 to the (A) ctDNA-based treatment group versus (B) the standard of care group. A total of 1320 patients will be randomized. Patients randomized to the ctDNA-based treatment group will have their post-surgery samples analysed directly after informed consent for MEDOCC-CrEATE. All patients with detectable ctDNA will be offered adjuvant chemotherapy (3 months CAPOX). Patients with undetectable ctDNA will receive routine follow-up at the surgical department. The aim of this Trial within Cohorts study is to investigate how many patients with detectable ctDNA after surgery start with adjuvant chemotherapy.",[26,27,28],"Circulating Tumor DNA","Recurrence","Colon Cancer Stage II","RECRUITING","2026-05-07",{"date":32,"type":33},"2026-05-12","ACTUAL",{"date":35,"type":33},"2020-03-05",{"date":37,"type":20},"2026-12",{"name":39,"class":40},"UMC Utrecht","OTHER",29,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100554166","danish-vulva-cancer-recurrence-study-100554166","NCT06495554","Danish Vulva Cancer Recurrence Study","The Value of Patient-reported Outcome Measure Assessment and Circulating Tumor-DNA to Detect Early Relapse During Surveillance in Women With Vulva Cancer","DaVulvaRec","Inclusion Criteria:\n\n* Primary or recurrent biopsy-verified squamous cell carcinoma of the vulva\n* ≥ 18 years of age\n* Able to understand oral and written information in Danish\n\nExclusion Criteria:\n\n* Active treatment for concurrent cancer and\u002For dissemination of concurrent cancer","FEMALE",{"count":52,"type":20},1295,[23],"The overall aim is to investigate different aspects of recurrence detection in women with vulva cancer (VC) to identify optimal treatment- and surveillance programs.\n\nDaVulvaRec is a Danish nationwide multicenter study with patient inclusion from Aarhus University Hospital and Rigshospitalet, Denmark. Applying a mixed method research design, the investigators will collect and analyze patient-reported outcome measures in combination with procedural data to evaluate symptomatology and map actions taken during the patient's pathway from primary disease to recurrence. Furthermore, the investigators aim to examine if circulating tumor-DNA (ctDNA) can be detected in liquid biopsies from VC patients. All patients will be followed for two years or until recurrence. Patient-reported outcome measures will be completed every four months during surveillance, and liquid biopsies will be collected prospectively for later analyses.\n\nTotal number of patients to be included is 295 according to a power calculation. All patients in the clinical study will be included in the intervention group, while data on a historical control group will be obtained from The Danish Gynecological Cancer Database. Hence, the control group will consist of 1000 VC patients diagnosed between 2011-2022.\n\nHypotheses:\n\n* All patients with VC will have specific tumor markers in the primary tumor that will be detectable in liquid biopsies as ctDNA at the time of diagnosis.\n* Measurement of ctDNA after primary treatment and during surveillance will allow detection of residual disease, improve allocation for adjuvant treatment, and will allow early detection of recurrent VC.\n* Proactive use of repeated PROM assessments in combination with procedural actions during surveillance will allow early detection of recurrent VC and early identification of late effects after treatment.",[56,57,58,59,60,61,62,26,63],"Vulva Cancer","Vulva Neoplasm","Vulvar Cancer","Vulva Disease","Vulvar Neoplasms","Vulvar Diseases","PROM","Survivorship","2026-04-28",{"date":66,"type":33},"2026-04-29",{"date":68,"type":33},"2024-08-15",{"date":70,"type":20},"2030-12-31",{"name":72,"class":40},"University of Aarhus",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100395818","phase-2-atezolizumab--sacituzumab-govitecan-to-prevent-recurrence-in-tnbc-aspria-100395818","NCT04434040","Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)","Inclusion Criteria:\n\n* Pathologically confirmed residual invasive breast cancer, in the breast and\u002For lymph node(s), following neoadjuvant chemotherapy. In the absence of residual invasive disease in the breast, lymph node must contain at least 2mm of invasive disease.\n* HER2 negative in primary tumor pre-treatment by local pathology assessed according to current ASCO\u002FCAP guidelines:\n\n  * In situ hybridization non-amplified (ratio of HER2 to CEP17 \\\u003C 2.0 or single probe average HER2 gene copy number \\\u003C 4 signals\u002Fcell), OR\n  * Immunohistochemistry (IHC) 0 or IHC 1+.\n  * NOTE: If more than one test result is available and not all results meet the inclusion criterion definition, all results should be discussed with the Principal Investigator to establish eligibility\n* ER and PR negative in primary tumor pre-treatment defined as \\\u003C 10% of cells expressing hormonal receptors via IHC analysis by local laboratory assessment.\n* Patients must have received neoadjuvant chemotherapy prior to breast surgery.\n* Patients must be within 4 months of completion of all locoregional therapy (either last surgery or last dose of radiation, whichever is later) . Definitive breast surgery must have been performed and includes lumpectomy or mastectomy with pathologically clear margins (i.e. no ink on tumor). For patients undergoing lumpectomy, this must be followed by whole breast irradiation. Definitive surgery also includes axillary surgery, either sentinel lymph node biopsy or axillary lymph node dissection at the discretion of the attending surgeon.\n* Evidence of ctDNA in blood sample collected after completion of all local and systemic neoadjuvant therapy (preoperative chemotherapy, surgery and radiation), confirmed by central testing. Detection of any tumor specific mutations (TSMs) within the sample will be considered positive for purposes of study eligibility.\n* Concurrent receipt of bone modifying agents (bisphosphonates or rank-ligand inhibitors)is allowed.\n* Prior treatment with an immune checkpoint inhibitor in the neoadjuvant setting is permitted.\n* ECOG Performance Status of 0 or 1\n* Men and women, age ≥ 18 years\n* Adequate hematologic and organ function defined by the following:\n\n  * ANC ≥ 1.5 × 109\u002FL (1500\u002FμL) without granulocyte colony-stimulating factor support\n  * WBC count ≥ 2.5 × 109\u002FL (2500\u002FμL)\n  * Absolute Lymphocyte count ≥ 0.5 × 109\u002FL (500\u002FμL)\n  * Platelet count ≥ 100 × 109\u002FL (100,000\u002FμL)\n  * Hemoglobin ≥ 90 g\u002FL (9.0 g\u002FdL), with or without transfusion\n  * AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 × institutional upper limit of normal (ULN).\n  * Serum bilirubin ≤ 1.5 × institutional ULN with the following exception:\n\n    * Patients with known Gilbert syndrome: serum bilirubin level ≤ 3 × institutional ULN\n  * Serum creatinine \\\u003C 1.5 x institutional ULN\n  * Creatinine clearance ≥30 mL\u002Fmin as assessed by the Cockcroft-Gault equation\n  * Serum albumin ≥ 25 g\u002FL (2.5 g\u002FdL)\n  * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 × institutional ULN\n  * For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n* Women of childbearing potential (pre-menopausal) must have a negative serum or urine pregnancy test within 7 days prior to start of therapy. A woman is defined as premenopausal if she is less than 12 months from last menstrual period with no identified cause other than menopause (medication induced amenorrhea is not acceptable). Pregnancy test is not required in women who are surgically sterile via bilateral salpingooophorectomy or hysterectomy.\n* Women of childbearing potential and men must agree to use adequate contraception for the duration of protocol treatment and for 6 months after last dose of atezolizumab and 6 months after last dose of sacituzumab govitecan, whichever is later. Hormonal contraceptives are not acceptable (see section 5.6).\n* Ability to understand and the willingness to sign a written informed consent document. Non-English speakers are eligible to participate but will be excluded from surveys\u002Fquestionnaires unless the participant has a proxy available for translation.\n\nExclusion Criteria:\n\n* Prior therapy with sacituzumab govitecan, irinotecan, or any topoisomerase I-containing antibody-drug conjugates at any time for early stage disease.\n* Receipt of adjuvant chemotherapy (all chemotherapy prior to registration must have occurred in the preoperative setting)\n* Prior hypersensitivity to atezolizumab or the excipients of atezolizumab or sacituzumab govitecan\n* Clinical or radiographic evidence of metastatic disease\n* Residual DCIS or LCIS alone without invasive cancer OR pT0N0i and pT0N1mic residual disease\n* Concurrent enrollment on another investigational therapy trial\n* Prior treatment-related toxicity must be resolved to ≤ Grade 1 prior to study enrollment with the exception of alopecia and peripheral neuropathy, prior to study enrollment.\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n* Intercurrent illness including, but not limited to: ongoing or active infection requiring systemic therapy, active tuberculosis, serious liver disease such as cirrhosis, active bleeding diathesis, uncontrolled Type I or Type II diabetes mellitus, Grade ≥ 2 uncontrolled or untreated hypercholesterolemia, Hypertriglyceridemia or hypercalcemia\n* Cardiovascular disease including: congestive heart failure of New York Heart Association Class III or IV, myocardial infarction (\\\u003C6 months prior to enrollment) unstable angina pectoris, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease, in the opinion of the investigator\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Active (acute or chronic) autoimmune disease of any type except hypothyroidism on a thyroid-replacement hormone, celiac disease, or well-controlled psoriasis, eczema, lichen simplex chronicus or vitiligo.\n* Impairment of gastrointestinal function or active gastrointestinal disease that may significantly alter the absorption of the study agents (e.g., ulcerative disease, uncontrolled nausea(\\> grade 2), vomiting (\\> grade 2), diarrhea (\\> grade 2), malabsorption syndrome or small bowel resection).\n* Congenital long QT syndrome or screening QT interval corrected through use of Fridericia's formula \\>480 ms.\n* Participants known to be positive for the human immunodeficiency virus (HIV), Hepatitis B antigen (HepBsAg), or Hepatitis C virus (HCV) RNA are ineligible.\n* History of prior invasive breast cancer in either breast.\n* Participants with history of prior malignancy other than breast cancer are eligible if they have been disease-free for at least 5 years prior to enrollment with the exception of patients with thyroid cancer that has been definitively treated without spread to regional lymph nodes.\n* Treatment with strong strong UGT1A1 inhibitor or inducer within 4 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine while on protocol treatment\n* Known allergy or hypersensitivity to any of the study drugs or any of their excipients, including chimeric or humanized antibodies or fusion proteins and Chinese hamster ovary cell products or recombinant human antibodies\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study, with the following exceptions:\n\n  * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible. o Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n* Pregnant women are excluded from this study because the effects of sacituzumab govitecan and atezolizumab on a developing fetus are unknown. Breastfeeding should be discontinued prior to entry onto the study and for one month following the last dose of sacituzumab govitecan.",{"count":82,"type":20},40,[84],"PHASE2","The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood.\n\nThis research study involves the following investigational drugs:\n\n* Sacituzumab govitecan\n* Atezolizumab",[87,88,89,26],"Breast Cancer","Triple Negative Breast Cancer","Residual Cancer",[87,88,89,26],{"date":92,"type":33},"2026-05-04",{"date":94,"type":33},"2020-07-02",{"date":96,"type":20},"2027-12-30",{"name":98,"class":40},"Dana-Farber Cancer Institute",7,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100441397","ctdna-as-a-novel-biomarker-of-treatment-efficacy-in-patients-with-ovarian-cancer-100441397","NCT05027828","CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer","Circulating Tumor DNA as a Novel Molecular Marker of Treatment Efficacy to Guide Targeted Maintenance Therapy for Patients With High Grade Serous Ovarian Cancer","Inclusion Criteria:\n\n1. Ovarian cancer first diagnosed and treated;\n2. Pathologically confirmed as epithelial ovarian cancer\u002Ffallopian tube cancer\u002Fprimary peritoneal cancer;\n3. The stage of the disease is II-IV, and surgery will be performed after evaluation;\n4. Age ≥ 18 years old;\n5. Subjects and their families fully understand the research plan and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Pathologically confirmed as non-epithelial ovarian cancer;\n2. Surgical treatment cannot be performed after evaluation;\n3. Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment;\n4. Patients who do not agree to use clinical first-line targeted drugs;\n5. Severe mental illness;\n6. Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.",{"count":108,"type":20},100,"OBSERVATIONAL","This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.",[112,26],"High-grade Serous Ovarian Cancer","2026-04-22",{"date":115,"type":33},"2026-04-24",{"date":117,"type":33},"2021-09-01",{"date":119,"type":20},"2027-09-30",{"name":121,"class":40},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":122},"100570459","nsclc-liquid-biopsies-and-exhaled-voc-100570459","NCT06707519","NSCLC Liquid Biopsies and Exhaled VOC","A Prospective, Single Center Study to Test the Validity and Feasibility of Circulating Tumor DNA in Blood, Sputum and Alveolar Fluid, as Well as Exhaled Volatile Organic Compounds as Biomarkers in Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patient must be at least 18 years of age\n* Patient must be able to provide consent\n* Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health.\n\nExclusion Criteria:\n\n* Resection done with non-curative intent or metastatic disease\n* other malignancies\n* Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).",{"count":131,"type":20},210,"The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for detecting mutations in extracted cell-free DNA in non-small cell lung cancer (NSCLC) patients, before and after surgery, and any recurrence within a 24-month postoperative follow-up period.\n\nThis is a pilot feasibility study, proposed as a 24-month prospective, single-center, non-interventional, observational trial with NSCLC-adenocarcinoma patients indicated for resection surgery with curative intent.",[134,26],"Lung Cancer","2026-04-21",{"date":113,"type":33},{"date":138,"type":33},"2023-02-01",{"date":140,"type":20},"2027-12-29",{"name":142,"class":40},"St. Joseph's Healthcare Hamilton",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":122},"100403253","interest-of-circulating-tumor-dna-in-digestive-and-gynecologicbreast-cancer-100403253","NCT04530890","Interest of Circulating Tumor DNA in Digestive and Gynecologic\u002FBreast Cancer","Inclusion Criteria:\n\n* Digestive or gynecological \u002F breast cancer proven or suspected, requiring oncological treatment (chemotherapy or immunotherapy)\n* Major patient\n* Patients benefiting from a Social Security scheme or benefiting through the intermediary of a third party\n* Information note and collection of non-opposition after clear and fair information about the study\n\nExclusion Criteria:\n\n* Linguistic or psychological refusal or inability to understand and \u002F or sign the information and no-objection note\n* History of a cancer other than that allowing inclusion in the 5 years preceding inclusion",{"count":150,"type":20},1000,[23],"Circulating tumor DNA (ctDNA) offers the possibility of accessing the tumor genome from circulating blood through a simple blood test. It is currently used for diagnostic, prognostic and predictive purposes of response or resistance to oncological treatments. These advances in ctDNA have been made possible by major developments in molecular biology techniques in recent years, as the detection of ctDNA requires very sensitive techniques such as Next Generation Sequencing (NGS).\n\nCtDNA overcomes this problem of very limiting tumor heterogeneity during a solid biopsy. All of these applications make circulating DNA an increasingly essential tool in the management of cancer patients. The studies are currently in most cases on small numbers and are retrospective.\n\nIn addition, exosomes are also a biomarker of the future that can also be detected in the bloodstream . Exosomes are nanovesicles 50 to 200 nm in diameter released into the extracellular environment via the endosomal pathway by fusion with the plasma membrane. They are very informative since they transport tumor genetic material in the form of DNA, mRNA and miRNA, but also adhesion proteins, immunostimulatory molecules and cytoskeleton, enzymes and Heats shock proteins ( HSP).\n\nThe aim of the ADIGYN study is to set up a large prospective cohort to assess the diagnostic, prognostic and predictive impact of ctDNA and exosomes in digestive and gynecological \u002F breast cancers. From the circulating DNA, we characterize the ActDNA on the molecular level thanks to the study of different point mutations usually used but also of new described mutations having a therapeutic impact and the search for other genetic alterations having an impact on the therapeutic strategy (such as microsatellite instability) or the study of exosomes and their composition. To assess resistance to oncological treatments, ctDNA will be analyzed at the start of treatment, during treatment, during progression and \u002F or relapse and also during monitoring or treatment break",[87,154,155,26,156],"Digestive Cancer","Gynecologic Cancer","Exosomes","2025-12-17",{"date":159,"type":33},"2025-12-24",{"date":161,"type":33},"2021-03-08",{"date":163,"type":20},"2032-03",{"name":165,"class":40},"Poitiers University Hospital",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":122},"100436699","phase-2-using-ctdna-to-determine-therapies-for-lung-cancer-100436699","NCT04966663","Using ctDNA to Determine Therapies for Lung Cancer","From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection","ctDNA Lung RCT","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of screening\n2. Written informed consent obtained from the subject prior to performing any protocol-related procedures\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n4. Weight ≥ 35 kg\n5. Must have a life expectancy of at least 24 months\n6. Complete surgical resection of T1-2N0M0 NSCLC or T3\u002FT4 multifocal NSCLC\n7. Any pathologic subtype of NSCLC is eligible, including adenocarcinoma and squamous carcinoma. Patients with targetable genomic alterations without approved or available targeted adjuvant therapy options are eligible\n8. Patients with detectable plasma ctDNA before or after complete surgical resection are eligible (RaDaR TM assay, Inivata Morrisville, North Carolina, USA).\n9. No prior chemotherapy or radiotherapy is allowed for the current diagnosis of resected NSCLC.\n10. Adequate organ and marrow function as defined in Table 4 (3.1.1)\n11. Females of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from screening to 180 days after the final dose of study treatment. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period\n12. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a male condom with spermicide from screening to 180 days after receipt of the final dose of study treatment. It is strongly recommended for the female partner of a male subject to also use a highly effective method of contraception throughout this period. In addition, male subjects must refrain from sperm donation while on study and for 180 days after the final dose of study treatment.\n\n4.1.2 Exclusion Criteria\n\n1. Participants that should receive adjuvant chemotherapy per standard of care (resected N1 or N2 disease, primary tumour \\>=4 cm).\n2. Receipt of any conventional or investigational anticancer therapy within 21 days or radiotherapy within 14 days prior to the scheduled first dose of study treatment;\n3. Prior receipt of any immune-mediated anti-cancer therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies including nivolumab and agents targeting CD73, CD39, or adenosine receptors;\n4. Incomplete surgical resection;\n5. Concurrent enrolment in another therapeutic clinical study of systemic anti-cancer treatment. Enrolment in observational or supportive studies will be allowed;\n6. Subjects with a recent history of myocardial infarction, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment;\n7. Active autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment. The following are exceptions to this criterion:\n\n   1. Subjects with vitiligo or alopecia.\n   2. Subjects with hypothyroidism (e.g., following Hashimoto syndrome) not requiring systemic treatment or stable on hormone replacement.\n   3. Subjects with psoriasis not requiring systemic treatment.\n   4. Any chronic skin condition that does not require systemic therapy.\n   5. Subjects with celiac disease controlled by diet alone;\n8. Have known uncontrolled human immunodeficiency virus (HIV)-1\u002F2 infection.\n\n   • Participants with HIV (known HIV 1\u002F2 antibodies positive) are allowed if all of the following conditions are met: CD4+ T-cell counts ≥350 cells\u002FuL; no opportunistic infection within the past 12 months; on established anti-retroviral therapy for at least 4 weeks; and an HIV viral load less than 400 copies\u002FmL.\n9. History of primary immunodeficiency, solid organ transplantation, or active tuberculosis (by clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice). In settings where there is clinical or radiographic evidence of tuberculosis, active disease must be excluded prior to enrolment. Subjects who have had adequately treated tuberculosis may be enrolled upon discussion with the coordinating Principal Investigator.\n10. Other invasive malignancy within 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are permitted.\n11. Known allergy or hypersensitivity to investigational product formulations.\n12. History of more than one event of infusion related reactions (IRR) requiring permanent discontinuation of IV drug treatment.\n13. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring antibiotic therapy, uncontrolled hypertension, bleeding diatheses, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.\n14. Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment. The following are exceptions to this criterion:\n\n    1. Intranasal, topical, inhaled corticosteroids or local steroid injections (e.g., intra articular injection).\n    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or equivalent.\n    3. Steroids as premedication for hypersensitivity reactions (e.g., computed tomography \\[CT\\] scan premedication).\n15. Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment (Note: Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of study treatment). Vaccination with an inactivated vaccine is permitted at any time.\n16. Major surgery (as defined by the investigator) within 28 days prior to the scheduled first dose of study treatment or still recovering from prior surgery. Local procedures (e.g., placement of a systemic port, core needle biopsy, etc) are allowed without needing to wait for the 28-day recovery period.\n17. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study.\n18. Subjects who are involuntarily incarcerated or are unable to willingly provide consent or are unable to comply with the protocol procedures.\n\n    Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results\n19. Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results.\n20. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in the study.",{"count":175,"type":20},66,[84],"This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.",[179,180,26],"Non Small Cell Lung Cancer","Complete Surgical Resection","2025-12-11",{"date":183,"type":33},"2025-12-18",{"date":185,"type":33},"2022-03-28",{"date":187,"type":20},"2026-12-01",{"name":189,"class":40},"University Health Network, Toronto",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100499741","ctdna-in-crc-patients-undergoing-curative-intent-surgery-for-liver-metastases-100499741","NCT05787197","ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases","Circulating Tumor DNA in Patients With Colorectal Cancer Undergoing Curative-intent Surgery for Liver Metastases: Prospective, Multicenter, GERCOR Cohort","CLIMES","Inclusion criteria\n\nThe patient will be included if:\n\n1. Has signed informed consent form and is willing to comply with all study procedures and availability for the study duration,\n2. Is ≥ 18 years of age,\n3. Has histologically confirmed colorectal adenocarcinoma,\n4. Has resected primary tumor or is eligible to primary tumor and CRLM (in case of synchronous metastases) resection within 6 months prior to study inclusion,\n5. Has isolated CRLM that is deemed resectable or potentially resectable (extrahepatic metastases excluded, except infracentimetric non-specific lung lesions with largest diameter \\\u003C1 cm and maximal number of ≤3) as judged by a multidisciplinary team meeting (based on CT scans of chest, abdomen, and pelvis \\[or MRI if CT not possible\\]),\n6. Is eligible to surgical procedure,\n7. Is fit for the chemotherapy-surgery combination treatment,\n8. Is registered in a national health care system (Protection Universelle Maladie \\[PUMa\\] included).\n\nExclusion criteria\n\nThe patient will be excluded if:\n\n1. Has definitively unresectable CLRM,\n2. Had more than 9 pre-operative cycles of chemotherapy for treatment of metastatic disease planned at inclusion,\n3. Has not resected primary rectal tumor (low and middle),\n4. Has history of another primary cancer within the last 5 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix,\n5. Has no more than two surgical procedures planned for complete resection of primary tumor and\u002For liver metastases,\n6. Has deficient mismatch repair (dMMR)\u002F microsatellite instability (MSI) tumors treated with immunotherapy,\n7. Blood samples cannot be collected if surgical procedure,\n8. Is pregnant or breastfeeding,\n9. Cannot be followed-up due to geographical, social, or psychic conditions,\n10. Has medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol,\n11. Is under guardianship, curatorship, or under the protection of justice.",{"count":199,"type":20},232,"This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of Colorectal cancer liver metastasis.",[202,26],"Metastatic Colorectal Cancer","2025-07-22",{"date":205,"type":33},"2025-07-23",{"date":207,"type":33},"2024-01-09",{"date":209,"type":20},"2027-06-30",{"name":211,"class":40},"GERCOR - Multidisciplinary Oncology Cooperative Group",16,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":122},"100485471","phase-2-circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer-100485471","NCT05601505","Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer","Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer --- a Multicenter Randomized Controlled Trial (CINTS-R)","CINTS-R","Inclusion Criteria:\n\n1. Aged 18-75 years;\n2. ECOG score 0-2;\n3. Rectal adenocarcinoma confirmed by pathology;\n4. The lower margin of the tumor was less than 12cm from the anal margin;\n5. Patients with clinical stage cT3-4N0M0 or cTanyN+M0;\n6. Newly treated patients who have not received treatment including radiotherapy, chemotherapy and surgery;\n7. Liver, kidney and other organs have good function and can tolerate radiotherapy, chemotherapy and surgery;\n8. Patients and family members can understand the study protocol, voluntarily participate in the study and sign informed consent.\n\nExclusion Criteria:\n\n1. ECOG score \\> 2;\n2. Patients with multiple primary colorectal cancers;\n3. A history of other malignant tumors (other than cured basal cell carcinoma, cervical carcinoma in situ, surgically treated localized prostate cancer, or surgically resected breast ductal carcinoma in situ) within the past 5 years;\n4. Complicated with intestinal obstruction, intestinal perforation, gastrointestinal bleeding and other patients requiring emergency surgery;\n5. pregnant or lactating women;\n6. Patients with a history of severe mental illness, immune disease, hormone medication;\n7. Patients contraindicated by MRI examination, chemoradiotherapy, immunotherapy or surgery;\n8. Participated in other clinical researchers in the past 3 months;\n9. Any other circumstances that the investigator considers inappropriate for inclusion.","75 Years",{"count":223,"type":20},470,[84],"Rectal cancer still remains one of the most popular tumors, however, distance metastasis still remains as high as 30% and the long-term survival outcomes are still unsatisfying. The recent conception of total neoadjuvant therapy and immune therapy is becoming popular and the oncologic effects are encouraging, especially in terms of circulating tumor DNA (ctDNA), the prognostic value of ctDNA has been demonstrated by our prior study. This study will carry out accurate ctDNA-guided neoadjuvant therapy on the basis of previous studies of the research group, and give appropriate treatment plans and treatment intensity to patients with different disease degrees. At the same time, combined with the latest progress in clinical diagnosis and treatment, the potential beneficiaries of immunotherapy were screened scientifically, and the combined immunotherapy was implemented accordingly.",[227,26],"Locally Advanced Rectal Carcinoma",[229,230,231,232,233],"Locally advanced rectal cancer","circulating tumor DNA","Neoadjuvant chemoradiotherapy","Total neoadjuvant therapy","Randomized Controlled Trial","2024-12-19",{"date":236,"type":33},"2024-12-24",{"date":238,"type":33},"2023-02-03",{"date":240,"type":20},"2026-11-01",{"name":242,"class":40},"Peking Union Medical College Hospital",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":252,"studyType":109,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":122},"100485242","exploring-the-mechanism-of-primary-resistance-to-third-generation-egfr-tkis-as-first-line-treatment-in-egfr-positive-advanced-nsclc-precise-study-100485242","NCT05598528","Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)","A Multicenter Clinical Study to Explore the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)","PRECISE","Inclusion Criteria:\n\n1. Age \\>18 years;\n2. Histological or cytopathological diagnosed NSCLC;\n3. According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is unresectable IIIB-IV or recurrence and metastasis after surgery;\n4. At least one measurable lesion can be evaluated according to the Response Evaluation Criteria In Solid Tumours v1.1 (RECIST1.1) criteria;\n5. Positive EGFR mutation confirmed by tissue or cytology (pleural fluid, cerebrospinal fluid, etc.);\n6. Use of third-generation EGFR-TKIs approved by the NMPA for NSCLC as first-line therapy;\n7. Cooperate with the provision of clinicopathological data, imaging data, sample collection, and follow-up required for the research process, and agree to use the test data for subsequent research and product development;\n8. Agree to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form;\n2. Pregnant and lactating women;\n3. Other malignant neoplastic diseases within 3 years;\n4. Patients who have undergone other clinical drug trials;\n5. Received systemic anti-tumor therapy within 2 years;",{"count":131,"type":20},"5 Years","Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), especially the 3rd-generation EGFR-TKIs have demonstrated strong antitumor effects in EGFR-positive patients.\n\nHowever, approximately 20% of EGFR-positive were primarily resistant to 3rd generation EGFR-TKIs, i.e., clinical non-response or disease progression in the short term.\n\nThis study aimed to clarify the molecular indicators that predict the benefits of 3-rd EGFR-TKIs as first-line therapy in NSCLCpatients with EGFR-positive. Further, to clarify their primary drug resistance mechanisms, which is of great significance for the treatment and clinical decision-making of NSCLC disease.",[255,256,257,258,26],"Lung Cancer, Non-small Cell","EGFR Gene Mutation","EGFR-TKI Resistant Mutation","Primary Resistance","2024-11-27",{"date":261,"type":33},"2024-12-02",{"date":263,"type":33},"2021-09-28",{"date":265,"type":20},"2026-12-31",{"name":267,"class":40},"Second Xiangya Hospital of Central South University",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":221,"enrollmentInfo":275,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":122},"100552928","clinical-application-of-ctdna-dynamic-monitoring-in-neoadjuvant-therapy-for-her2-positive-breast-cancer-patients-100552928","NCT06479460","Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients","Director, Department of Pathology, Jiangsu Provincial People's Hospital","Inclusion Criteria:\n\n1. Women with breast cancer diagnosed clinically and pathologically, aged 18-75 years;\n2. ECOG performance score is 0-1;\n3. Histologically confirmed as early or locally advanced invasive breast cancer: the diameter of the primary tumor is more than 2 cm, and HER2 is positive (confirmed by IHC or FISH).\n4. The patient did not receive any treatment for breast cancer before enrollment;\n5. Having lesions measurable according to RECIST 1.1 standards;\n6. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up; 7) Breast cancer patients who plan to use neoadjuvant therapy.\n\nExclusion criteria\n\n1. Patients with known metastatic or stage IV breast cancer;\n2. There are other untreated malignant tumors other than breast cancer;\n3. Patients with one or more serious systemic diseases that, in the eyes of researchers, can impair their ability to complete research;\n4. According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the subjects or the collection of experimental data.\n5. Unable to follow up with the study according to the determined clinical follow-up period;\n6. Cannot accept or provide specified efficacy evaluation methods such as CT.\n7. Unable to obtain sufficient tumor tissue samples or peripheral blood samples.\n\nExclusion Criteria:\n\n\\- 1) Patients with known metastatic or stage IV breast cancer; 2) There are other incurable malignant tumors present; 3) One or more serious systemic diseases that, in the eyes of researchers, can impair the patient's ability to complete the study; 4) According to the researcher's judgment, there are other factors that may cause the subject to be forced to terminate the study midway, such as other serious illnesses (including mental illness) requiring concurrent treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the subject or the collection of trial data.\n\n5\\) Unable to follow the determined clinical follow-up period in conjunction with the study for follow-up; 6) Unable to accept or provide specified efficacy evaluation methods such as CT.",{"count":276,"type":20},50,"1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population;\n2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.",[87,279,280,26],"Neoadjuvant","HER2-positive Breast Cancer",[282,230,283],"breast cancer","MRD","2024-07-23",{"date":286,"type":33},"2024-07-24",{"date":288,"type":33},"2024-03-08",{"date":290,"type":20},"2026-03-31",{"name":292,"class":40},"The First Affiliated Hospital with Nanjing Medical University",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":122},"100479948","circulating-tumor-dna-guided-adjuvant-chemotherapy-for-colon-cancer-100479948","NCT05529615","Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer","Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial","CTAC","Inclusion Criteria:\n\n1. Age: 18 to 75\n2. Colon adenocarcinoma confirmed by pathology (including high and high differentiated tubular adenocarcinoma, papillary adenocarcinoma, low differentiated adenocarcinoma, mucinous adenocarcinoma and signet ring cell carcinoma)\n3. Postoperative pathology is stage II with high-risk factors or stage III;\n\n   High risk stage II refers to stage II colon cancer with at least one of the following:\n\n   a) T4 stage; b) The number of lymph nodes detected was less than 12; c) Poor differentiation (except MSI-H); d) Complicated with LVI or PNI；e) Complicated with obstruction or perforation.\n4. No distant metastasis was found in preoperative imaging examination and operation;\n5. ECOG score: 0-2 points;\n6. MSS\u002FpMMR and BRAF wild type\n7. Start time of chemotherapy is less than 2 months from the operation\n8. Have sufficient organ functions;\n9. The baseline blood routine and biochemical indexes of the subject meet the following standards:\n\n   * hemoglobin ≥ 9.0 g \u002F dl;\n   * absolute neutrophil count (ANC) ≥ 1500 \u002F mm3;\n   * platelet count ≥ 100000 \u002F mm3;\n   * total bilirubin ≤ 1.5 times the upper limit of normal value (ULN);\n   * glutamic pyruvic transaminase and glutamic oxalic transaminase ≤ 2.5 times ULN;\n   * creatinine ≤ 1.5 times ULN;\n10. Patients or family members who can understand the study protocol and are willing to participate in the study shall provide written informed consent.\n\nExclusion Criteria:\n\n1. Receive chemotherapy, radiotherapy or immunotherapy before operation\n2. History of malignant tumor in the past 5 years (except fully cured cervical carcinoma in situ or basal cell carcinoma or squamous epithelial cell skin cancer)\n3. Pregnant women\n4. Serious mental illness\n5. Those with poor physical condition and difficult to complete chemotherapy\n6. Patients or family members cannot understand the conditions and objectives of this study",{"count":302,"type":20},2684,[23],"The IDEA study classified stage III colon cancer into low-risk (T1-3\u002FN1) and high-risk patients (T4 or N2) according to TNM stage. The results showed that for some low-risk patients, chemotherapy could be reduced without survival loss.\n\nIn recent years, circulating tumor DNA had achieved encouraging results in monitoring recurrence and metastasis after surgery, and has potential clinical application value. Postoperative ctDNA is also considered as a marker of increased risk of recurrence for stage I-III colon cancer and can provide predictive information for decision making on adjuvant treatment.\n\nThe results of GERCOR-PRODIGE, concomitant study of IDEA-FRANCE, showed that in the high-risk group, the patients with ctDNA positive and receiving adjuvant chemotherapy for 6 months had similar prognosis as the patients with ctDNA negative and receiving chemotherapy for 3 months; in the low-risk group, the patients with ctDNA positive but receiving chemotherapy for 3 months had worst prognosis, and the prognosis of patients with ctDNA negative chemotherapy for 3 months and 6 months and ctDNA positive chemotherapy for 6 months were similar. This indicates that risk stratification can be further performed according to the results of ctDNA after clinical pathological staging. Pathological staging is still an important decision-making factor for chemotherapy. It is not reliable to the chemotherapy decision making just based on ctDNA and abandoning clinical staging.\n\nTherefore, a prospective, multicenter, open-label, randomized controlled clinical trial was designed aimed to investigate circulating tumor DNA guided adjuvant chemotherapy for colon cancer. In this study, all the patients are divided into high-risk group and low-risk group according to the postoperative pathology. Patients in each group were randomized to different treatment schedule according to the results of ctDNA.",[306,26],"Colon Cancer",[308,309,310,311],"chemotherapy","ctDNA","colon cancer","prognosis","2022-09-06",{"date":314,"type":33},"2022-09-07",{"date":316,"type":20},"2022-11-01",{"date":318,"type":20},"2029-05-01",{"name":320,"class":40},"Peking University Cancer Hospital & Institute"]